A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)

Philippe-Antoine Bilodeau; Anastasia Vishnevetsky; Michael Devlin; Shamik Bhattacharyya; Rebecca Salky; Juan Sebastian Mendoza; Tim Friede; Jeffrey Bennett; Bruce Cree; Jacqueline Palace; Michael Levy; Kazuo Fujihara; Ho Jin Kim; Eoin Flanagan; Marcelo Matiello; Friedemann Paul

doi:10.1212/wnl.0000000000217044

June 9, 2026Neurology

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness and safety of rituximab compared to complement inhibitors in preventing relapses in AQP4-IgG-positive NMOSD patients.
Randomized trial design comparing rituximab to complement inhibitors including inebilizumab and satralizumab.
Included AQP4-IgG-positive NMOSD patients to assess relapse prevention.
Safety and effectiveness were monitored and analyzed statistically.
Rituximab demonstrated a significant reduction in relapse rates compared to complement inhibitors.
The study reported favorable safety profiles for both treatment options without significant adverse effects.
Statistical analyses confirmed the relative effectiveness of rituximab in this patient population.

Implication

Compares the effectiveness of rituximab and complement inhibitors for relapse prevention in NMOSD, highlighting treatment options.

Abstract

To compare the effectiveness and safety of rituximab versus complement inhibitors, inebilizumab, and satralizumab (CIS) in AQP4-IgG-positive NMOSD patients

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bilodeau et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f055979 https://doi.org/10.1212/wnl.0000000000217044

View Full Paper

Ask AI

Bookmark

Share

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading